Greenwich Total Stockholder Equity vs Accounts Payable Analysis

GLSI Stock

USD 14.25 0.32 2.20%

Greenwich Lifesciences financial indicator trend analysis is much more than just examining Greenwich Lifesciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Greenwich Lifesciences is a good investment. Please check the relationship between Greenwich Lifesciences Total Stockholder Equity and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

Total Stockholder Equity vs Accounts Payable

Total Stockholder Equity vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Greenwich Lifesciences Total Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Greenwich Lifesciences' Total Stockholder Equity and Accounts Payable is -0.25. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Greenwich Lifesciences, assuming nothing else is changed. The correlation between historical values of Greenwich Lifesciences' Total Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Greenwich Lifesciences are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Stockholder Equity i.e., Greenwich Lifesciences' Total Stockholder Equity and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.25

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Accounts Payable

An accounting item on the balance sheet that represents Greenwich Lifesciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Greenwich Lifesciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Greenwich Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Greenwich Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.The Greenwich Lifesciences' current Enterprise Value is estimated to increase to about 240.3 M, while Selling General Administrative is projected to decrease to under 1.2 M.

	2021	2023	2024 (projected)
Reconciled Depreciation	3.6K	4.2K	4.0K
Total Operating Expenses	4.6M	9.3M	5.3M

Reconciled Depreciation Total Operating Expenses

Greenwich Lifesciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Intangible Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt
Total Assets		-0.15	-0.21	0.95	-0.04	0.77	-1.0	-0.37	-0.23	1.0	-0.55	1.0	0.41	0.62	-0.7	0.84	-0.71	0.95	1.0	0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Other Current Liab	-0.15		0.9	-0.22	0.27	-0.41	0.15	0.55	0.54	-0.15	0.55	-0.15	-0.65	-0.51	0.29	-0.4	0.3	-0.22	-0.15	-0.32	-0.2	0.55	-0.34	0.45	-0.44	0.45
Total Current Liabilities	-0.21	0.9		-0.23	0.33	-0.43	0.22	0.56	0.82	-0.22	0.54	-0.22	-0.5	-0.56	0.19	-0.41	0.2	-0.23	-0.22	-0.26	-0.26	0.54	-0.3	0.52	-0.5	0.52
Total Stockholder Equity	0.95	-0.22	-0.23		-0.28	0.91	-0.96	-0.6	-0.25	0.95	-0.75	0.95	0.63	0.77	-0.88	0.95	-0.88	1.0	0.95	0.89	0.98	-0.75	0.9	-0.92	0.94	-0.92
Other Liab	-0.04	0.27	0.33	-0.28		-0.58	0.06	0.83	0.58	-0.05	0.72	-0.05	-0.65	-0.76	0.47	-0.44	0.48	-0.28	-0.05	-0.46	-0.21	0.72	-0.45	0.43	-0.45	0.43
Net Tangible Assets	0.77	-0.41	-0.43	0.91	-0.58		-0.78	-0.87	-0.46	0.77	-0.95	0.77	0.83	0.92	-0.93	0.99	-0.93	0.91	0.77	0.95	0.84	-0.95	0.96	-0.98	0.98	-0.98
Net Debt	-1.0	0.15	0.22	-0.96	0.06	-0.78		0.38	0.24	-1.0	0.56	-1.0	-0.42	-0.63	0.71	-0.85	0.71	-0.96	-1.0	-0.74	-0.99	0.56	-0.77	0.84	-0.86	0.84
Retained Earnings	-0.37	0.55	0.56	-0.6	0.83	-0.87	0.38		0.58	-0.37	0.98	-0.37	-0.91	-0.9	0.79	-0.79	0.8	-0.6	-0.37	-0.8	-0.49	0.98	-0.8	0.8	-0.79	0.8
Accounts Payable	-0.23	0.54	0.82	-0.25	0.58	-0.46	0.24	0.58		-0.23	0.52	-0.23	-0.32	-0.66	0.12	-0.38	0.13	-0.25	-0.23	-0.2	-0.32	0.52	-0.24	0.5	-0.49	0.5
Cash	1.0	-0.15	-0.22	0.95	-0.05	0.77	-1.0	-0.37	-0.23		-0.55	1.0	0.41	0.62	-0.7	0.84	-0.71	0.95	1.0	0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Non Current Assets Total	-0.55	0.55	0.54	-0.75	0.72	-0.95	0.56	0.98	0.52	-0.55		-0.55	-0.93	-0.92	0.88	-0.9	0.89	-0.75	-0.55	-0.9	-0.64	1.0	-0.91	0.9	-0.89	0.9
Cash And Short Term Investments	1.0	-0.15	-0.22	0.95	-0.05	0.77	-1.0	-0.37	-0.23	1.0	-0.55		0.41	0.62	-0.7	0.84	-0.71	0.95	1.0	0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Common Stock Total Equity	0.41	-0.65	-0.5	0.63	-0.65	0.83	-0.42	-0.91	-0.32	0.41	-0.93	0.41		0.8	-0.86	0.8	-0.86	0.63	0.41	0.85	0.5	-0.93	0.84	-0.76	0.75	-0.76
Common Stock Shares Outstanding	0.62	-0.51	-0.56	0.77	-0.76	0.92	-0.63	-0.9	-0.66	0.62	-0.92	0.62	0.8		-0.77	0.85	-0.77	0.77	0.62	0.77	0.74	-0.92	0.79	-0.86	0.89	-0.86
Non Current Liabilities Total	-0.7	0.29	0.19	-0.88	0.47	-0.93	0.71	0.79	0.12	-0.7	0.88	-0.7	-0.86	-0.77		-0.94	1.0	-0.88	-0.7	-0.99	-0.75	0.88	-0.98	0.87	-0.88	0.87
Other Stockholder Equity	0.84	-0.4	-0.41	0.95	-0.44	0.99	-0.85	-0.79	-0.38	0.84	-0.9	0.84	0.8	0.85	-0.94		-0.94	0.95	0.84	0.96	0.88	-0.9	0.98	-0.99	0.98	-0.99
Total Liab	-0.71	0.3	0.2	-0.88	0.48	-0.93	0.71	0.8	0.13	-0.71	0.89	-0.71	-0.86	-0.77	1.0	-0.94		-0.88	-0.71	-0.99	-0.75	0.89	-0.98	0.88	-0.88	0.88
Net Invested Capital	0.95	-0.22	-0.23	1.0	-0.28	0.91	-0.96	-0.6	-0.25	0.95	-0.75	0.95	0.63	0.77	-0.88	0.95	-0.88		0.95	0.89	0.98	-0.75	0.9	-0.92	0.94	-0.92
Total Current Assets	1.0	-0.15	-0.22	0.95	-0.05	0.77	-1.0	-0.37	-0.23	1.0	-0.55	1.0	0.41	0.62	-0.7	0.84	-0.71	0.95		0.74	0.98	-0.55	0.76	-0.83	0.85	-0.83
Capital Stock	0.74	-0.32	-0.26	0.89	-0.46	0.95	-0.74	-0.8	-0.2	0.74	-0.9	0.74	0.85	0.77	-0.99	0.96	-0.99	0.89	0.74		0.77	-0.9	1.0	-0.92	0.91	-0.92
Net Working Capital	0.98	-0.2	-0.26	0.98	-0.21	0.84	-0.99	-0.49	-0.32	0.98	-0.64	0.98	0.5	0.74	-0.75	0.88	-0.75	0.98	0.98	0.77		-0.64	0.8	-0.87	0.9	-0.87
Intangible Assets	-0.55	0.55	0.54	-0.75	0.72	-0.95	0.56	0.98	0.52	-0.55	1.0	-0.55	-0.93	-0.92	0.88	-0.9	0.89	-0.75	-0.55	-0.9	-0.64		-0.91	0.9	-0.89	0.9
Common Stock	0.76	-0.34	-0.3	0.9	-0.45	0.96	-0.77	-0.8	-0.24	0.76	-0.91	0.76	0.84	0.79	-0.98	0.98	-0.98	0.9	0.76	1.0	0.8	-0.91		-0.94	0.93	-0.94
Short Long Term Debt Total	-0.83	0.45	0.52	-0.92	0.43	-0.98	0.84	0.8	0.5	-0.83	0.9	-0.83	-0.76	-0.86	0.87	-0.99	0.88	-0.92	-0.83	-0.92	-0.87	0.9	-0.94		-0.99	1.0
Current Deferred Revenue	0.85	-0.44	-0.5	0.94	-0.45	0.98	-0.86	-0.79	-0.49	0.85	-0.89	0.85	0.75	0.89	-0.88	0.98	-0.88	0.94	0.85	0.91	0.9	-0.89	0.93	-0.99		-0.99
Short Term Debt	-0.83	0.45	0.52	-0.92	0.43	-0.98	0.84	0.8	0.5	-0.83	0.9	-0.83	-0.76	-0.86	0.87	-0.99	0.88	-0.92	-0.83	-0.92	-0.87	0.9	-0.94	1.0	-0.99

Click cells to compare fundamentals

Greenwich Lifesciences Account Relationship Matchups

Greenwich Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	26.7K	28.7M	27.2M	13.5M	7.0M	6.6M
Other Current Liab	646.8K	770.3K	164.3K	42.1K	258.9K	311.1K
Total Current Liabilities	1.4M	1.0M	385.2K	262.9K	294.4K	545.8K
Total Stockholder Equity	(1.4M)	27.6M	26.8M	13.2M	6.7M	11.5M
Net Debt	(6.2K)	(28.7M)	(27.2M)	(13.5M)	(7.0M)	(7.3M)
Retained Earnings	(27.2M)	(29.1M)	(33.6M)	(41.5M)	(50.4M)	(52.9M)
Cash	6.8K	28.7M	27.2M	13.5M	7.0M	6.6M
Non Current Assets Total	19.8K	16.2K	12.6K	9.0K	5.4K	5.1K
Cash And Short Term Investments	6.8K	28.7M	27.2M	13.5M	7.0M	6.6M
Common Stock Shares Outstanding	11.7M	12.7M	12.9M	12.9M	12.8M	13.8M
Liabilities And Stockholders Equity	26.7K	28.7M	27.2M	13.5M	7.0M	6.6M
Other Stockholder Equity	25.9M	56.7M	60.5M	54.7M	57.1M	49.2M
Total Liab	1.4M	1.0M	385.2K	262.9K	294.4K	279.7K
Net Invested Capital	(1.4M)	27.6M	26.8M	13.2M	6.7M	11.5M
Total Current Assets	6.8K	28.7M	27.2M	13.5M	7.0M	6.6M
Capital Stock	10.4K	12.7K	13.1K	12.8K	14.8K	11.8K
Net Working Capital	(1.4M)	27.6M	26.8M	13.2M	6.7M	13.3M
Intangible Assets	19.8K	16.2K	12.6K	9.0K	5.4K	5.1K
Common Stock	8.5K	12.7K	13.1K	12.8K	14.8K	11.0K

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:

How To Invest In Greenwich

Details

Is Greenwich Stock a good investment?

Details

What is Greenwich Lifesciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.81)

Return On Assets

(0.72)

Return On Equity

(1.24)

The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Greenwich Total Stockholder Equity vs Accounts Payable Analysis

Total Stockholder Equity vs Accounts Payable

Total Stockholder Equity vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Accounts Payable

Greenwich Lifesciences fundamental ratios Correlations

Greenwich Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Greenwich Lifesciences fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Short Term Debt	- 0.99	Current Deferred Revenue
Current Deferred Revenue	- 0.99	Short Long Term Debt Total